Alkermes says J&J will not pursue 4-w... - Reuters

Alkermes says J&J module not pursue 4-wk risperidone
Reuters
... which collects income for manufacturing a version of the injectable drug which lasts for two weeks, down nearly 12 percent in after-hours trading. ...